154 related articles for article (PubMed ID: 34236267)
1. A bivalent cyclic RGD-siRNA conjugate enhances the antitumor effect of apatinib via co-inhibiting VEGFR2 in non-small cell lung cancer xenografts.
Liao L; Cen B; Li G; Wei Y; Wang Z; Huang W; He S; Yuan Y; Ji A
Drug Deliv; 2021 Dec; 28(1):1432-1442. PubMed ID: 34236267
[TBL] [Abstract][Full Text] [Related]
2. An Efficient Bivalent Cyclic RGD-PIK3CB siRNA Conjugate for Specific Targeted Therapy against Glioblastoma In Vitro and In Vivo.
Cen B; Wei Y; Huang W; Teng M; He S; Li J; Wang W; He G; Bai X; Liu X; Yuan Y; Pan X; Ji A
Mol Ther Nucleic Acids; 2018 Dec; 13():220-232. PubMed ID: 30312846
[TBL] [Abstract][Full Text] [Related]
3. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
4. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Watanabe H; Ichihara E; Kayatani H; Makimoto G; Ninomiya K; Nishii K; Higo H; Ando C; Okawa S; Nakasuka T; Kano H; Hara N; Hirabae A; Kato Y; Ninomiya T; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Cancer Sci; 2021 May; 112(5):1853-1864. PubMed ID: 33410241
[TBL] [Abstract][Full Text] [Related]
5. The effect of apatinib combined with chemotherapy or targeted therapy on non-small cell lung cancer in vitro and vivo.
Liu M; Wang X; Li H; Xu L; Jing L; Jiang P; Liu B; Li Y
Thorac Cancer; 2019 Oct; 10(10):1868-1878. PubMed ID: 31486270
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts.
Chen S; Liu X; Gong W; Yang H; Luo D; Zuo X; Li W; Wu P; Liu L; Xu Q; Ji A
Oncol Rep; 2013 Jan; 29(1):260-8. PubMed ID: 23117577
[TBL] [Abstract][Full Text] [Related]
7. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
8. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
[TBL] [Abstract][Full Text] [Related]
9. Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA.
Liu X; Wang W; Samarsky D; Liu L; Xu Q; Zhang W; Zhu G; Wu P; Zuo X; Deng H; Zhang J; Wu Z; Chen X; Zhao L; Qiu Z; Zhang Z; Zeng Q; Yang W; Zhang B; Ji A
Nucleic Acids Res; 2014 Oct; 42(18):11805-17. PubMed ID: 25223783
[TBL] [Abstract][Full Text] [Related]
10. Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy.
Liu L; Liu X; Xu Q; Wu P; Zuo X; Zhang J; Deng H; Wu Z; Ji A
Int J Nanomedicine; 2014; 9():3509-26. PubMed ID: 25114522
[TBL] [Abstract][Full Text] [Related]
11. Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer-bearing mice and patients.
Liu M; Li H; Wang X; Jing L; Jiang P; Li Y
Cancer Med; 2020 Apr; 9(8):2660-2673. PubMed ID: 32073228
[TBL] [Abstract][Full Text] [Related]
12. Apatinib Inhibits Angiogenesis in Intrahepatic Cholangiocarcinoma by Regulating the Vascular Endothelial Growth Factor Receptor-2/Signal Transducer and Activator of Transcription Factor 3/Hypoxia Inducible Factor 1 Subunit Alpha Signaling Axis.
Huang MP; Gu SZ; Huang B; Li GW; Xiong ZP; Tang T; Zeng SN
Pharmacology; 2021; 106(9-10):509-519. PubMed ID: 34412054
[TBL] [Abstract][Full Text] [Related]
13. [Silence of VEGFR2 expression mediated by PEI/siRNA complexes].
Yang H; Che O; Chen S; Sun L; Ji AM
Yao Xue Xue Bao; 2010 May; 45(5):576-81. PubMed ID: 20931758
[TBL] [Abstract][Full Text] [Related]
14. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
15. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
16. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
17. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
Kim KL; Suh W
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3592-3599. PubMed ID: 28715845
[TBL] [Abstract][Full Text] [Related]
18. Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
Xiang Y; Li Q; Huang D; Tang X; Wang L; Shi Y; Zhang W; Yang T; Xiao C; Wang J
Exp Biol Med (Maywood); 2015 Feb; 240(2):160-8. PubMed ID: 25125500
[TBL] [Abstract][Full Text] [Related]
19. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.
Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J
Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891
[TBL] [Abstract][Full Text] [Related]
20. Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways.
Pal HC; Sharma S; Strickland LR; Agarwal J; Athar M; Elmets CA; Afaq F
PLoS One; 2013; 8(10):e77270. PubMed ID: 24124611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]